Loading
Life sciences · Journal article
Biomedicines · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pulmonary arterial hypertension (PAH) exhibits substantial biological heterogeneity that may contribute to variable therapeutic responses and complicate the translation of immunotherapies from experimental models to patients. This Review examines how cross-species variation and biological sex may modify PAH immunotherapeutic responses, with particular attention to differences between target-directed biologics and active immunization. Species-related variation in model fidelity, target conservation, and immune biology, together with sex-associated differences in vascular and immune phenotypes, may contribute to heterogeneous therapeutic responses. These effects may be particularly relevant to active immunization because vaccine efficacy depends on multiple host-dependent immune processes. However, direct evidence for species- and sex-associated differences in PAH vaccine efficacy remains limited, and PAH-specific mechanistic evidence should be distinguished from extrapolation based on broader immunology. We therefore discuss a translational strategy integrating mechanism-guided model selection, cross-species validation, sex-stratified study design, human-relevant experimental systems, and multidimensional analysis to improve the design and interpretation of future PAH immunotherapy studies.